Search clinical trials for: BRCA1 Mutation

Total 3372 results

AstraZeneca

Completed

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population (C-PATROL)

Ovarian Cancer, Hereditary Ovarian Cancer Syndrome

Germany
Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT) (BRCA-HRT)

Hereditary Breast and Ovarian Cancer

Spain
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations

Breast Cancer | Ovarian Cancer

United States
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
AstraZeneca

Completed

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (BRCA)

Ovarian Cancer

India
Beth Israel Deaconess Medical Center
Johns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca

Active, not recruiting

Olaparib In Metastatic Breast Cancer

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States
AstraZeneca

Completed

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (ICEBERG 3)

Ovarian Neoplasms

Spain, United States, Belgium, United Kingdom, Israel, Poland, Germany, Sweden, Australia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ovarian Carcinoma

United States, Korea, Republic of
Georgetown University
National Cancer Institute (NCI)

Completed

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

Breast Cancer

United States
AstraZeneca

Recruiting

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (ERA)

Breast Cancer

Russian Federation
Institut de Cancérologie de Lorraine

Completed

Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer (BOVARY Pilot)

Ovarian Cancer

France
University Health Network, Toronto

Withdrawn

Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT

Breast Cancer
European Institute of Oncology

Recruiting

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients (LobularCard)

BRCA1 Mutation | BRCA2 Mutation | Lobular Breast Carcinoma | Lobular in Situ Breast Carcinoma

Italy
Women's College Hospital
Canadian Institutes of Health Research (CIHR); London Health Sciences Centre; H. Lee Moffitt Cancer Center and Research Institute and other collaborators

Unknown

Cancer Prevention in Women With a BRCA Mutation

Breast Cancer | Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation

Canada
AstraZeneca

Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Ovarian Neoplasms | BRCA1 Protein | BRCA2 Protein

Netherlands, Belgium, United Kingdom, Poland
The Netherlands Cancer Institute
Radboud University Medical Center; Erasmus Medical Center; Dutch Cancer Society

Unknown

Health After eaRly Menopause Due to Oophorectomy (HARMOny)

Cardiovascular Diseases | Quality of Life | Cognitive Decline | BRCA1 Mutation | BRCA2 Mutation | Bone Mineral Density | Surgical Menopause | Menopause Surgical

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | PALB2 Gene Mutation | ATM Gene Mutation

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

Metastatic Adenocarcinoma of the Pancreas | Germline BRCA1/2 Mutations and

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Germany, Korea, Republic of, Australia, Israel, Netherlands
VA Office of Research and Development

Recruiting

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

Metastatic Castrate Resistant Prostate Cancer | BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | RAD51B, RAD51C, RAD51D, or RAD54L Mutations

United States
The National Institute of Lymphology
The DrMarga Practice Group; The Center for Restorative Breast Surgery, LLC

Unknown

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired Lymphedema

United States
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Methods in Education for Breast Cancer Genetics

Breast Cancer | Ovarian Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Leiden University Medical Center
University Medical Center Groningen; Erasmus Medical Center

Recruiting

Functional Analysis of BRCAness (FAB)

BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm Epithelial

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States
Bahria University

Completed

Ethnic Predisposition, Risk Factors & Breast Cancer Presentation. (BC)

Breast Cancer

Pakistan
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer (ICEBERG 1)

Breast Neoplasms

Sweden, United States, United Kingdom, Germany, Spain, Australia, Israel, Canada
AstraZeneca

Completed

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

United States, Canada
Women and Infants Hospital of Rhode Island

Completed

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Nerviano Medical Sciences

Active, not recruiting

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

United States, United Kingdom, China, Italy, Bulgaria, Hungary
National Cancer Institute (NCI)

Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Mesothelioma | Familial Cancer | BRCA1-Associated Protein-1 (BAP1) Mutations | Tumor Predisposition Syndrome (TPDS)

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Genetics and Heart Health After Cancer Therapy (Gene-HEART)

Heart Diseases | Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Drug-Induced Cardiomyopathy

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
Centro di Riferimento Oncologico - Aviano

Recruiting

InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2 (IDENTITY)

Breast Cancer

Italy
Columbia University

Recruiting

Pancreatic Cancer Genetics

Pancreatic Cancer

United States
Abramson Cancer Center at Penn Medicine

Terminated

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Pancreatic Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
Spanish Breast Cancer Research Group
AstraZeneca

Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast)

Advanced Breast Cancer

Spain
Russian Academy of Medical Sciences

Completed

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

Early Triple Negative Breast Cancer

Russian Federation
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

Greece
Columbia University

Terminated

Validation of a Mouse Model of Pancreatic Carcinogenesis

Pancreatic Cancer

United States
University Hospital, Montpellier

Completed

Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests (PSICOM)

Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer
M.D. Anderson Cancer Center
Lynne Cohen Foundation for Ovarian Cancer Research

Completed

Lynne Cohen Consortium Project: Multi-Center Database/Registry

Breast Cancer | Ovarian Cancer

United States
Lei Li

Completed

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | Chinese | Homologous Recombination Genes

China
Lei Li

Unknown

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | Chinese

China

Search clinical trials for: BRCA1 Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations